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Abstract Osteocalcin (OC) is produced by osteoblasts
and vascular smooth muscle cells. In animal models, serum
OC levels are strongly correlated with vascular calcium
content, however, the association of OC with vascular
calciﬁcation in humans is uncertain. The Study of Osteo-
porotic Fractures (SOF) enrolled community-living
women, age C65 years. The present study included a
subsample of 363 randomly selected SOF participants.
Serum total OC was measured by ELISA, and abdominal
aortic calciﬁcation (AAC) was evaluated on lateral lumbar
radiographs. We examined the cross-sectional association
between serum OC and AAC. The mean serum OC level
was 24 ± 11 ng/ml and AAC was present in 188 subjects
(52%). We observed no association of OC and AAC in
either unadjusted or adjusted analyses. For example, each
standard deviation higher OC level was associated with an
odds ratio (OR) for AAC prevalence (AAC score[0) near
unity (OR = 1.06; 95% CI, 0.82–1.36) in models adjusted
for CVD risk factors. Further adjustment for intact para-
thyroid hormone, bone-speciﬁc alkaline phosphatase, 25-
hydroxyvitamin D, and hip and spine bone mineral density
did not materially change the results (OR = 1.22; 95% CI,
0.86–1.75). Similarly, higher OC levels were not associated
with severity of AAC (P=0.87). In conclusion, among
community-living older women, serum OC is not associ-
ated with AAC. These ﬁndings suggest that serum OC
levels may more closely reﬂect bone formation than vas-
cular calciﬁcation in humans.
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Cardiovascular disease (CVD) is the leading cause of death
in older women [1], and traditional risk factors are less
strongly associated with CVD events in women compared
to men [2–5]. Prevalent vascular calciﬁcation has demon-
strated utility in predicting CVD events in healthy com-
munity-living populations [6]. Previously thought to reﬂect
an inevitable consequence of aging, recent studies dem-
onstrate that vascular calciﬁcation is actively regulated,
and several novel regulatory proteins have been identiﬁed
[7]. One such protein is osteocalcin (OC) [8].
OC (a.k.a. bone gla protein) is traditionally considered a
marker of osteoblast activity [9, 10], as it is produced in
osteoblasts and is associated with high bone turnover and
decreased bone mineral density (BMD) in a variety of
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DOI 10.1007/s00223-010-9332-9clinical settings [11–13]. However, OC is also produced by
calcifying vascular smooth muscle cells. In rodent models,
serum OC levels are strongly associated with vascular
calcium content, and treatment with bisphosphonates
decreases vascular calciﬁcation and simultaneously lowers
serum OC levels [14]. In pathologic studies in humans, OC
levels are higher in calciﬁed atherosclerotic plaques and
calciﬁed cardiac valves than in noncalciﬁed vasculature
[15]. These data suggest that higher serum OC levels may
be useful as a marker of vascular calcium deposition and
severity in humans. However, the association of serum OC
levels and vascular calciﬁcation and CVD events has not
been extensively studied, and the existing data are
conﬂicting.
To that end, we evaluated the association between OC
levels with abdominal aortic calciﬁcation (AAC) among a
well-characterized cohort of older women who participated
in the Study of Osteoporotic Fractures (SOF). We
hypothesized that higher OC levels would be associated
with a greater prevalent and severity of AAC, independent
of traditional CVD risk factors, kidney function, or BMD.
Methods
Study Participants
The SOF is a multicenter observational study designed to
identify risk factors for osteoporotic fractures in postmen-
opausal women. Methods have been described previously
[16]. In brief, 9704 community-dwelling women aged
C65 years were recruited from population-based listings in
Baltimore, Maryland; Minneapolis, Minnesota; the Mono-
ngahela Valley, Pennsylvania; and Portland, Oregon.
Recruitment involved mailings to women on population-
based lists (voter registration, driver’s license, and health
maintenance organization lists). Women with bilateral hip
replacements or who were unable to walk without assis-
tance were excluded. African-American women were ini-
tially excluded because of their low incidence of hip
fracture. The institutional review boards at the four clinical
sites and the coordinating center approved the study pro-
tocol. All participants provided informed consent.
From 1986 to 1988, baseline examinations were per-
formed, which included physical examination, health status
questionnaires, dietary history, medical history, lateral
lumbar radiographs, and collection of blood specimens. A
sample of 400 women was selected at random for serum
OC measurement. Of these, 3 subjects were excluded due
to missing OC measurements and 34 were excluded for
missing or technically uninterpretable lumbar radiographs
for evaluation of AAC, resulting in a ﬁnal analytic sample
of 363 women for this analysis.
Osteocalcin
A detailed description of OC measurement has been
reported previously [17]. Brieﬂy, OC was measured in
serum that had been stored at -190C at the Biomedical
Research Institute (Rockville, MD). Total OC was mea-
sured with a human-speciﬁc immunoradiometric assay
(ELSA-OSTEO; CIS BioInternational, Baglos/Ceze,
France), which recognizes a large N-terminal midfragment
in addition to the intact molecule. Intra- and interassay
coefﬁcients of variation were \4 and \6%, respectively
[17]. All assays were performed in 1994 and 1995,
7–8 years after initial serum collection.
Abdominal Aortic Calciﬁcation
Lateral lumbar radiographs were taken with a tube-to-ﬁlm
distance of 101.6 cm, centered at the third lumbar verte-
brate (L3). From these, ACC scores [18] were determined
by grading the severity of calciﬁcation in the abdominal
aorta between the L1 and the L4 lumbar vertebrae. The
radiodensity of the aortic wall was assessed at each ver-
tebral segment, and calciﬁc deposits were regarded as
present if densities were visible in an area parallel to the
lumbar spine and anterior to the lower part of the spine in
the usual anatomic location of the abdominal aorta.
Densities overlapping the vertebrae were deemed to rep-
resent AAC only if they extended from or formed a clear
pattern with those of the lower part of the aorta. Calciﬁc
densities were graded on a scale of 0 to 3 at each lumbar
vertebral segment. A score of 0 denoted no aortic calciﬁc
deposits; 1, small scattered calciﬁc deposits, ﬁlling less
than one-third of the longitudinal wall of the aorta; 2,
calciﬁcation involving between one-third and two-thirds
of the longitudinal wall of the aorta; and 3, calciﬁcation
involving two-thirds or more of the longitudinal wall of
the aorta. A separate score was determined for the ante-
rior and posterior aorta, and the values were summed
across the four vertebrae, resulting in an AAC score that
could range from 0 to 24 points. All radiographs were
assessed by a single reader who was blinded to all clinical
data. Intraobserver variability of 30 randomly selected
radiographs showed 93% agreement between the ﬁrst and
the second readings, for a j value of 0.87 (lower bound of
CI: 0.54) [19].
Other Measurements
Participants were weighed wearing light clothes and no
shoes on a balance-beam scale and height was measured
using a standard held-expiration technique with a wall-
mounted Harpenden stadiometer. Body mass index (BMI)
was calculated (kg/m
2). Blood pressure measurements
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artery using an appropriately sized cuff by sphygmoma-
nometer (Baum Co., New York). Hypertension was
deﬁned as systolic blood pressure [140 mmHg, diastolic
blood pressure[90 mmHg, or use of diuretics. Sensitivity
analysis, where hypertension was deﬁned only based on
systolic and diastolic blood pressure criteria yielded
identical results in the ﬁnal analyses. Use of other anti-
hypertensive medications was not recorded at the baseline
study visit. Questionnaires [20, 21] provided age; history
of diabetes, stroke, osteoporosis, and fractures after age
50; cigarette use; use of select medications (calcium
supplements, vitamin D supplements, estrogen, steroids,
and diuretics); and years since menopause. Dietary cal-
cium, protein, and phosphorus intake was estimated with
a validated food frequency questionnaire, developed from
the Second National Health and Nutrition Examination
Survey [22].
Blood specimens collected at the baseline visit were
used to measure creatinine, C-reactive protein, 25-hy-
droxyvitamin D, and intact parathyroid hormone (PTH)
levels. Serum creatinine was measured with the use of an
automated analyzer and was combined with age, gender,
and race to estimate glomerular ﬁltration rate (eGFR) by
the four-variable Modiﬁcation of Diet in Renal Disease
Study (MDRD) equation [23]. Chronic kidney disease was
deﬁned as an eGFR\60 ml/min/1.73 m
2 [24]. C-Reactive
protein level was measured by a high-sensitivity enzyme-
linked immunosorbent assay (ELISA) based on puriﬁed
protein and polyclonal anti-C-reactive-protein antibodies
(Calbiochem, La Jolla, CA) [25]. Intact PTH (interassay
variability, 8.5%) was measured by immunoradiometric
assay (IRMA), and serum 25-hydroxyvitamin D (interassay
variability, 15%) was measured by radioimmunoassay at
the University of California, San Francisco, Calciotropic
Hormone Reference Laboratory [26]. Serum bone-speciﬁc
alkaline phosphatase (interassay variability, \9%) was
measured with an IRMA using two monoclonal antibodies
against the human bone isoenzyme (Ostate; Hybriteck,
Inc., San Diego, CA) [27].
Hip and spine BMD were not evaluated at the baseline
study visit but were measured at the ﬁrst follow-up visit
among 83% (N = 303) of participants, an average of
3.8 years (range, 3.3–5.1 years) after their baseline visit.
Detailed descriptions of BMD are given elsewhere [28]. In
brief, BMD of the proximal femur and spine was measured
in the anteroposterior projection visit using a Hologic QDR
1000 scanner (Hologic, Inc., Waltham, MD). Coefﬁcients
of variation were 1.2 and 1.5%, respectively. All mea-
surements were made on the right except in the rare
instances when subjects reported a stroke, fracture, or
severe injury involving the right limb, in which case the
left side was used.
Statistical Analysis
A priori, we elected to evaluate serum OC levels on a
continuous scale (per standard deviation [SD] increase) as
our primary predictor variable. However, for descriptive
statistics, we categorized participants by tertiles of serum
OC levels and compared baseline characteristics using
analysis of variance (ANOVA) or the Kruskal–Wallis test
for continuous variables and the chi-square test or Fisher’s
exact test for categorical variables, as appropriate. Tertiles
were chosen to provide a cursory evaluation of the linearity
of associations, while simultaneously maximizing the
number of subjects in each category.
We categorized AAC as present (AAC score[0) or
absent as the primary outcome variable. Multivariable
logistic regression evaluated the association of OC with
AAC prevalence. The initial model was age adjusted. The
second model was adjusted for established CVD risk fac-
tors (age, BMI, systolic and diastolic blood pressure, dia-
betes, hypertension, smoking, estrogen use, eGFR, and C-
reactive protein). The ﬁnal model adjusted for all variables
in the second model, with additional adjustment for hor-
mone regulators of bone metabolism (intact PTH, bone-
speciﬁc alkaline phosphatase, 25-hydroxyvitamin D) and
hip and spine BMD. Among participants with prevalent
AAC (AAC score[0), the relationship between OC and
AAC severity [(ln)AAC score] was evaluated by linear
regression in companion analyses. Model adjustment fol-
lowed the identical sequence outlined above. This rela-
tionship is expressed as a percentage difference in AAC
score. The distribution of OC levels was evaluated by
graphical methods and was approximately normally dis-
tributed, with a few high-value outliers. We evaluate OC
levels on a continuous scale, per SD increase. In sensitivity
analysis, exclusion of the few high outliers resulted in
similar ﬁndings, so data presented retain the outliers within
the analysis. All analyses were performed using Stata
Statistical Software, version 9.2 (College Station, TX).
Results
Among the 363 study participants, the mean age was
72 ± 5 years, 65% had hypertension, and 9% had diabetes
mellitus. OC was approximately normally distributed
across the study sample, with a mean ± SD of 24 ± 11 ng/
ml (Fig. 1). AAC was present in 188 subjects (52%).
Among these, AAC scores were positively skewed, with a
median score of 4.5 (interquartile range, 2.0–8.0).
Compared to subjects in the lowest OC tertile, those
with higher OC levels were less likely to be taking calcium
supplements or estrogen replacement and had lower
C-reactive protein, higher intact PTH and bone-speciﬁc
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levels, and lower hip and spine BMD measurements
(Table 1). Subjects in either the high or the low OC tertile
were more likely to have smoked than subjects with
intermediate OC levels.
After adjustment for age, the association of OC levels
and prevalent AAC was near unity (Table 2). Adjustment
for CVD risk factors, markers of mineral metabolism, and
BMD had little effect on this association. Findings were
similar when evaluating the association of OC with AAC
severity (Table 3). Low 25-hydroxyvitamin D (\30 ng/
ml) was present in 70% of women and there was no sig-
niﬁcant association between OC and AAC when women
were grouped by 25-hydroxyvitamin D status (P for
interaction = 0.41). Roughly half of the women had intact
PTH levels [30 pg/ml and results were similar among
persons with intact PTH levels above or below this level (P
for interaction = 0.85).
Discussion
We found no evidence of an association between serum OC
levels and AAC prevalence or severity among community-
living older women. The association remained near unity
despite adjustment for CVD risk factors, estrogen use,
kidney function, 25-hydroxyvitamin D, intact parathyroid
hormone, bone-speciﬁc alkaline phosphatase, and BMD.
Serum OC levels may have limited utility as a marker of
AAC in humans.
Prior studies evaluating the association of OC with
vascular calciﬁcation and CVD have been conﬂicting. A
recent study among 328 persons with diabetes from Japan
demonstrated that higher OC levels were associated with
decreased vascular stiffness and lower carotid intimal
medial thickness in men but not women [29]. This ﬁnding
is intriguing not only because of the gender differences, but
also because vascular calciﬁcation is strongly linked with
both vascular stiffness and atherosclerosis in humans [30,
31], and because higher OC levels are associated with
vascular calciﬁcation in animal models. Thus the directions
of association observed in this study are opposite to that
observed in experimental animals. In contrast, Fahrleitner-
Pammer et al. [32] followed 135 subjects with CKD for
4 years, 35 of whom experienced CVD events during fol-
low-up. Baseline OC levels were higher in subjects who
had CVD events in unadjusted analysis, but the association
was not statistically signiﬁcant in multivariable models. To
our knowledge, only two prior studies have evaluated the
association of serum OC levels and AAC [33, 34]. Both
studies were relatively small, and neither adjusted for tra-
ditional CVD risk factors, kidney function, or BMD. In
one, higher OC trended toward higher prevalence of AAC
[33], whereas higher OC trended toward lower prevalence
of AAC in the other study [34], although the associations
were not signiﬁcant in either analysis. One possible
explanation is the use of different OC assays (due to dif-
fering speciﬁcities for OC fragments, accumulation of
fragments with kidney dysfunction, and degradation of
intact OC with storage). However, using an alternative
assay, the data presented here conﬁrm the absence of an
association of OC with AAC prevalence and extend these
data by demonstrating that OC levels are also not associ-
ated with AAC severity, and that the results remain similar
despite adjustment for traditional CVD risk factors, kidney
function, and markers of bone turnover and BMD.
The absence of an association of OC with AAC may,
however, make OC a more useful marker of bone turnover
without competing inﬂuences of vascular calciﬁcation as
both processes frequently coexist in older persons [19, 35–
37]. Prior in vitro and animal studies demonstrated that OC
was associated with vascular calciﬁcation, but the data
presented here suggest that such relationships are not easily
detected with serum OC levels in humans. While it might
be expected that serum OC levels would be higher in
individuals with increased vascular calciﬁcation, other
Fig. 1 Distribution of serum
osteocalcin levels among older
women
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OC levels. For instance, the major source of circulating OC
is likely from bone-resident osteoblasts [10, 38], so any
contribution of OC to the circulating pool from vascular
smooth muscle cells or myoﬁbroblasts may be too small in
comparison to be reliably detected by measurement at one
point in time in serum.
Other factors such as vitamin K intake and warfarin use
are potentially important determinants of OC activity.
Vitamin K-dependent carboxylation of OC glutamate res-
idues (a process inhibited by warfarin) enables OC to bind
hydroxyapatite. Vitamin K intake and warfarin use were
not recorded in this study, so it remains possible that
associations may have differed in individuals with vitamin
Table 1 Participant characteristics by osteocalcin tertile
Osteocalcin, ng/ml P value
Tertile 1
(\18.8; n = 121)
Tertile 2
(18.8–25.8; n = 121)
Tertile 3
([25.8; n = 121)
Age, years 72 (5%) 72 (5%) 72 (5%) 0.39
Medical history
Diabetes, No. 15 (12%) 11 (9%) 7 (6%) 0.20
Chronic kidney disease
a, No. 35 (29%) 32 (27%) 34 (28%) 0.92
Hypertension, No. 81 (67%) 85 (70%) 71 (59%) 0.15
History of heart failure, No. 3 (3%) 3 (3%) 5 (5%) 0.75
History of myocardial infarction, No. 9 (9%) 6 (6%) 7 (7%) 0.72
History of stroke, No. 3 (3%) 1 (1%) 2 (2%) 0.60
Osteoporosis or vertebral fracture, No. 24 (20%) 22 (18%) 12 (10%) 0.09
Years since menopause 23 (7) 23 (9) 25 (8) 0.08
History of ever smoking, No. 57 (48%) 36 (30%) 49 (41%) 0.02
Pack years
b for those who smoked 28 (23) 27 (20) 26 (24) 0.96
Current medication use
Calcium supplements, No. 77 (64%) 66 (55%) 52 (43%) 0.005
Vitamin D, No. 58 (48%) 53 (48%) 48 (40%) 0.43
Estrogen, No. 27 (22%) 5 (4%) 1 (1%) \0.001
Steroids use, No. 3 (2%) 2 (2%) 0 (0%) 0.24
Diuretics, No. 41 (34%) 40 (33%) 31 (26%) 0.31
Measurements
Body mass index, kg/m
2 27 (5) 27 (5) 26 (4) 0.23
Systolic blood pressure, mmHg 143 (20) 145 (22) 140 (22) 0.24
Diastolic blood pressure, mmHg 76 (9) 78 (9) 77 (11) 0.35
C-reactive protein, median lg/dl (IQR) 2.1 (1.3–3.6) 1.7 (1.0–3.0) 1.5 (0.8–2.5) 0.001
eGFR,
c ml/min/1.73 m
2 70 (14) 72 (17) 69 (15) 0.30
Serum calcium, mg/dl 9.7 (0.5) 9.7 (0.4) 9.7 (0.5) 0.70
iPTH, median pg/ml (IQR) 28 (20–37) 30 (22–39) 33 (26–45) 0.003
Bone-speciﬁc alk phos, median ng/ml (IQR) 9.6 (7.8–11.8) 11.6 (9.6–14.0) 15.0 (11.8–20.0) \0.001
25 (OH) vitamin D, ng/ml 27 (11) 27 (12) 24 (9) 0.03
Hip bone mineral density, g/cm
2 0.80 (0.13) 0.76 (0.11) 0.74 (0.13) \0.001
Spine bone mineral density, g/cm
2 0.90 (0.17) 0.85 (0.13) 0.83 (0.16) 0.02
Dietary calcium intake, median g/week (IQR) 4.3 (3.1–6.1) 4.3 (2.6–6.0) 4.1 (2.7–6.4) 0.76
Dietary phosphorus intake, g/week 6.7 (3.0) 6.6 (3.1) 6.6 (2.7) 0.98
Dietary protein intake, g/week 345 (126) 347 (140) 343 (127) 0.98
alk phos Alkaline phosphatase, eGFR estimated glomerular ﬁltration rate, iPTH intact parathyroid hormone, IQR interquartile range,
OH hydroxylated. Data are presented as mean (SD) unless speciﬁed otherwise
a Chronic kidney disease: eGFR\60 ml/min/1.73 m
2
b Pack years = number of years smoking 9 (number of cigarettes per day /20)
c Calculated using the Modiﬁcation of Diet in Renal Disease (MDRD) Study equation: 186 9 (Scr)
-1.154 9 (Age)
-0.203 9 0.742 for
non-African-American females
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123K deﬁciency or in warfarin users. This question requires
future study.
Strengths of this study include the availability of OC,
AAC,traditionalCVDriskfactors,mineralmetabolism,and
BMD measurements concurrently among a well-character-
ized cohort of older women. The study also has important
limitations. First, while more than half of participants had
prevalent AAC, improving the statistical power, the study
sample was relatively small. We cannot exclude the possi-
bility thatanassociationofOC with AAC wasmisseddueto
chanceorthatotherimagingmodalitiesmayhavebeenmore
sensitive.Resultsshouldbeinterpretedwithintheconﬁnesof
the 95% conﬁdence intervals. Second, all participants were
older women and were almost exclusively Caucasian.
Resultsmaynotgeneralizetoyoungerpersons,men,orother
race/ethnicities. Two factors which affect OC activation
(vitamin K status and warfarin use) were not measured. The
assayforOCusedinourstudydoesnotdiscriminatebetween
carboxylated and uncarboxylated OC, and measurement of
these speciﬁc forms of OC may provide different results.
Finally, our analysis is limited by its cross-sectional design,
so temporal direction of associations could not be assessed.
In conclusion, in community-living older women, serum
OC levels are not associated with either AAC prevalence or
severity. It is likely that serum total OC more strongly
reﬂects bone osteoblast activity than vascular smooth
muscle cell calciﬁcation. These data do not support the use
of OC as a marker of vascular calciﬁcation in humans.
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